MEVION S250 Achieves Outstanding First-Year Clinical Results
In its first year, the MEVION S250 was used to treat pediatric and adult tumors in the intercranial and craniospinal regions, and adult tumors in the lungs.
I'm proud to share a major milestone for Mevion -- the release of clinical data from our first year of treating patients with the MEVION S250.
The results are remarkable. The MEVION S250 took just 11 months to treat its first 100 patients -- the fastest per room ramp-up of any proton therapy system. Additionally, the system demonstrated efficient treatment times; an impressive 97 percent operational uptime just five months after opening; and the ability to treat a diverse and complex array of cancers.
Of course, we could not have done this without our partners at the S. Lee Kling Proton Therapy Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, where the world's first MEVION S250 went into service just over a year ago.
Specific results just released by the Center include:
- The MEVION S250 delivered more than 6,700 clinical proton treatment fields to 118 patients
- Of the 118 patients, approximately 25 percent were children and 75 percent were adults
- Of the adult tumors treated, 43 percent were in the brain, 27 percent were in the lungs, 11 percent were in the prostate and 8 percent were in the esophagus
- The MEVION S250 treated more than 20 patients in a single day and in a single work shift
As you know, Mevion's goal is to make leading-edge proton therapy accessible to any size cancer care facility-giving as many patients as possible access to a promising form of radiation therapy. These results are a game changer. They prove the MEVION S250's revolutionary design enables cancer centers to treat complex cases precisely, effectively, and in a cost- and time-efficient way.
But most of all, we are proud that during the past year so many patients have benefited from Mevion's advanced technology. More information is in the press release below from Barnes-Jewish Hospital and Washington University School of Medicine. I hope you'll take a moment to read it and reflect on what this milestone means to the cancer patients and their families who have had the opportunity to be treated with Mevion's advanced technology over the past year
Joseph K. Jachinowski
President and Chief Executive Officer
Mevion Medical Systems
S. Lee Kling Proton Therapy Center Completes First Year of Patient Care
In its first year of operation, more than 100 cancer patients have received an innovative form of radiation therapy at the S. Lee Kling Proton Therapy Center.
The treatments, which utilize the world's first proton system of its kind, are provided at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis. Proton therapy is a precise form of radiation that targets tumors while sparing surrounding healthy tissues, making it ideal for treating pediatric cancer patients, as well as adults, with tumors in sensitive locations such as near the heart or brain. The new technology delivers the same targeted, noninvasive treatments as conventional proton systems but is considerably smaller in size and cost.
"We offer proton therapy to patients we think would benefit from this particular technology, such as children and those with tumors in the brain or around the spinal cord," said Jeffrey Bradley, MD, Washington University radiation oncologist and director of the S. Lee Kling Proton Therapy Center. "We offer a full suite of cancer treatments, and this technology helps to meet the healthcare needs of the patients we serve."
Since December 2013, the new system:
- Delivered more than 6,700 clinical proton treatment fields to 118 patients. (One treatment field equals the use of a single proton beam. Each patient receives two or three treatment fields per therapy session.) Of the 118 patients, approximately 25 percent were children and 75 percent were adults;
- Addressed a variety of complex tumors. Of adult tumors treated, 43 percent were in the brain, 27 percent were in the lungs, 11 percent were in the prostate and 8 percent were in the esophagus; and
- Treated more than 20 patients in a single day and in a single work shift.
Lawrence Barry, a 62-year-old from St. Louis, just finished proton therapy treatments at Siteman for a rare brain tumor. The tumor had been causing severe headaches and memory loss until it was surgically removed. Barry's Washington University radiation oncologist, Clifford Robinson, MD, recommended proton therapy instead of X-ray radiation as a follow-up treatment. "For every patient, we make a thoughtful decision about whether proton therapy is the best option," said Robinson, assistant professor of radiation oncology at Washington University. "In Mr. Barry's case, we decided to use protons because it would decrease substantially the radiation dose to his heart, lungs and bowels. In addition, proton therapy reduces the side effects sometimes caused by X-ray radiation, such as such as nausea, diarrhea and fatigue."
A superconducting synchrocyclotron proton accelerator is a key component of the proton therapy system. The relatively small size of the device allows it to fit in a single room that isn't much larger than a traditional radiation therapy room. The cost of this single-vault proton therapy system was about $25 million. That represents a fraction of the investment needed for traditional proton therapy systems, which typically are housed in football field-sized buildings and cost more than $150 million.
Littleton, Mass.-based Mevion Medical Systems developed and manufactured the technology, called the MEVION S250 Proton Therapy System. Radiation oncologists and physicists at Washington University in St. Louis worked with Mevion to develop and refine the proton therapy technology.
The proton therapy center was named after the late S. Lee Kling, a visionary St. Louisan who traveled to the East Coast to receive proton therapy for an eye tumor. Kling, a former chairman of The Foundation for Barnes-Jewish Hospital's board of directors, believed the therapy should be more accessible and available to patients in St. Louis. As a result, Kling, along with family and friends, established the S. Lee Kling chair in radiation oncology to help lead the proton center's development and to conduct research into the most effective ways to use this new technology. The center serves the St. Louis region and the Midwest. The next closest location offering proton therapy is in the Chicago area, about 280 miles away.
Washington University School of Medicine's 2,100 employed and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient-care institutions in the nation, currently ranked sixth in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
Siteman Cancer Center, the only National Cancer Institute-designated Comprehensive Cancer Center in Missouri, is ranked among the top cancer facilities in the nation by U.S. News & World Report. Comprising the cancer research, prevention and treatment programs of Barnes-Jewish Hospital and Washington University School of Medicine, Siteman is also Missouri's only member of the National Comprehensive Cancer Network.
About Mevion Medical Systems
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion's flagship product, the MEVION S250 proton therapy platform, is the only modular, single room proton therapy system currently on the market. The MEVION S250 integrates with standard radiation therapy workflow and provides a proton therapy treatment environment at a fraction of the cost, footprint and operational complexity of conventional systems.
Mevion is privately held and based in Littleton, Massachusetts, with international offices in the United Kingdom and Japan. For more information, please visit www.mevion.com.
HYPERSCAN has not been cleared by the USFDA for clinical use.